Heart Transplant clinical trials at UCLA
4 in progress, 2 open to eligible people
XVIVO Heart Perfusion System (XHPS) With Supplemented XVIVO Heart Solution (SXHS)
open to eligible people ages 18 years and up
The purpose of this study is to evaluate if Non-Ischemic Heart Preservation (NIHP) of extended criteria donor hearts using the XVIVO Heart Preservation System (XHPS) is a safe and effective way to preserve and transport hearts for transplantation.
Los Angeles, California and other locations
Diagnostic and Therapeutic Applications of Microarrays in Heart Transplantation
open to eligible people ages 18 years and up
Demonstrate the impact of the Molecular Microscope Diagnostic System as the standard of care for heart transplant patients.
Los Angeles, California and other locations
Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score
Sorry, in progress, not accepting new patients
The TEAMMATE Trial will enroll 210 pediatric heart transplant patients from 25 centers at 6 months post-transplant and follow each patient for 2.5 years. Half of the participants will receive everolimus and low-dose tacrolimus and the other half will receive tacrolimus and mycophenolate mofetil. The trial will determine which treatment is better at reducing the cumulative risk of coronary artery vasculopathy, chronic kidney disease and biopsy proven-acute cellular rejection without an increase in graft loss due to all causes (e.g. infection, PTLD, antibody mediated rejection).
Los Angeles, California and other locations
Surveillance HeartCare® Outcomes Registry
Sorry, in progress, not accepting new patients
This is an observational registry to assess the clinical utility of surveillance using HeartCare testing services, in association with clinical care of heart transplant recipients.
Los Angeles, California and other locations
Our lead scientists for Heart Transplant research studies include Abbas Ardehali, MD.